Celerion expands Swiss bioanalytical laboratory capacity
pharmafile | June 29, 2026 | News story | Research and Development | bioanalytical laboratory
Celerion has expanded its bioanalytical laboratory in Zurich, Switzerland, to increase capacity for drug development programmes and support growing global demand for bioanalytical services.
The investment includes additional scientific staff and new laboratory technologies designed to support increasingly complex medicines, including gene therapies, biosimilars and biologics.
Bioanalytical testing plays a key role in clinical development by measuring how medicines are absorbed, distributed and processed in the body, helping researchers evaluate safety and efficacy during clinical trials.
The Zurich laboratory provides services including pharmacokinetic analysis, immunogenicity testing, biomarker assays, biosimilar support, gene therapy analytics and metabolite profiling. It is integrated with Celerion’s clinical research units in the UK and US to support sample management and rapid data delivery.
Chad Briscoe, Executive Vice President of Global Bioanalytical Services at Celerion, said: “This expansion reflects both the growth of the bioanalytical market and the increasing demand we are seeing from our clients worldwide.”
He added that the investment would expand capacity while maintaining the scientific quality needed to support drug development programmes.
The facility is located within one of Europe’s largest life sciences hubs and forms part of Celerion’s global laboratory network.
Susan Thornton, CEO of Celerion, said increasingly complex therapeutic modalities required bioanalytical partners capable of scaling alongside evolving development programmes.
She added: “This investment ensures we remain well-positioned to deliver the expertise, quality, and responsiveness that help accelerate the development of new medicines.”
The expanded laboratory is now fully operational and supporting new and ongoing clinical studies, with the company aiming to accelerate development of new medicines through enhanced laboratory capacity and scientific expertise.
